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Diabetes mellitus is a public health problem which leads to serious complications over time. 
Experimentally, many herbs have been recommended for treating diabetes. In most cases, however, the 
recommendations are based on animal studies and limited pieces of evidence exist about their clinical 
usefulness. This review focused on the herbs, the hypoglycemic actions of which have been supported 
by three or more clinical studies. The search was done in Google Scholar, Medline and Science Direct 
databases using the key terms diabetes, plants, herbs, glucose and patients. According to the clinical 
studies, Aegle marmelos, Allium cepa, Gymnema sylvestre, Momordica charantia, Ocimum sanctum, 
Nigella sativa, Ocimum sanctum, Panax quinquefolius, Salacia reticulate, Silybum marianum and 
Trigonella foenum-graecum have shown hypoglycemic and, in some cases, hypolipidemic activities 
in diabetic patients. Among them, Gymnema sylvestre, Momordica charantia, Silybum marianum and 
Trigonella foenum-graecum have acquired enough reputation for managing diabetes. Thus, it seems 
that physicians can rely on these herbs and advise for the patients to improve management of diabetes.
Uniterms: Medicinal plants/diabetes treatment. Diabetes/treatment. Diabetes/clinical trials.
Diabetes mellitus é um problema de saúde pública que leva a complicações graves ao longo do tempo. 
Experimentalmente, muitas ervas têm sido recomendadas para o tratamento da diabetes. Contudo, na maior 
parte dos casos as recomendações são baseadas em estudos em animais e existem evidências limitadas 
sobre a sua utilidade clínica. Esta revisão tem como foco as ervas nas quais as ações hipooglicêmicas são 
apoiadas por três ou mais estudos clínicos. Realizou-se pesquisa no Google Scholar, Medline e Science 
Direct utilizando palavras-chave diabete, plantas, ervas, glicose e pacientes. Segundo os estudos clínicos, 
Aegle marmelos, Allium cepa, Gymnema sylvestre, Momordica charantia, Ocimum sanctum, Nigella 
sativa, Ocimum sanctum, Panax quinquefolius, Salacia reticulate, Silybum marianum e Trigonella 
foenum-graecum mostraram atividade hipoglicêmica e, em alguns casos, hipolipidêmica em pacientes 
diabéticos. Entre elas, Gymnema sylvestre, Momordica charantia, Silybum marianum e Trigonella foenum-
graecum apresentam grande reputação no manejamento da diabetes. Portanto, parece que os médicos 
podem confiar nessas ervas e aconselhar aos pacientes para que melhorem o tratamento da diabetes.
Unitermos: Planta medicinais/tratamento da diabetes. Diabetes/tratamento. Diabetes/ensaios clínicos.
INTRODUCTION
Diabetes mellitus is a growing public health problem 
in both developed and developing countries. According 
to the report of World Health Organization (August, 
2011), 346 million people have diabetes worldwide. 
It is also estimated that 3.4 million patients died from 
diabetes-related complications in 2004. Without urgent 
action, this number is likely to double by 2030. Generally, 
diabetes is classified to two main types: type-1 diabetes 
(T1D), previously known as insulin-dependent diabetes 
mellitus, and type-2 diabetes (T2D), formerly called 
non-insulin-dependent diabetes mellitus. Patients with 
T1D show a state of insulin deficiency because of severe 
defect in islet β-cell function while T2D is characterized 
by a combination of resistance to action of insulin and 
insufficiency in insulin secretion (Deshpande et al., 2008).
Over time, both types of diabetes lead to serious 
complications in the body, which include nephropathy, 
retinopathy, neuropathy, dyslipidemia and cardiovascular 
diseases (Deshpande et al., 2008; Ghorbani et al., 2010). 
Currently, beside insulin, the most widely used medication 
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for diabetes are oral hypoglycemic drugs including insulin 
sensitizers (biguanides, thiazolidinediones), insulin 
secretagogues (sulfonylureas, meglitinides), α-glucosidase 
inhibitors, incretin agonists and dipeptidyl peptidase-4 
inhibitors (Lorenzati et al., 2010). Although early onset 
complications of diabetes can be controlled by oral 
hypoglycemic drugs/insulin treatment, serious late onset 
complications emerge in many patients (Tzoulaki et al., 
2009). Furthermore, clinical uses of the current drugs are 
accompanied by unpleasant side effects such as severe 
hypoglycemia, lactic acidosis, peripheral edema and 
abdominal discomfort (Lorenzati et al., 2010). Therefore, 
the search for new antidiabetic agents with more 
effectiveness and less side effects has been continued.
Medicinal plants have always been an important 
source for finding new remedies for human health 
problems. Traditionally, numerous herbs have been 
recommended for treatment of diabetes. Also, antidiabetic 
effects of so many plants have been reported by many 
researchers. In most cases, however, these reports are 
confirmed by animal models and even in vitro studies and 
limited evidence exists about their clinical usefulness. 
The current review focused on the medicinal plants, the 
hypoglycemic actions of which have been supported by 
different clinical studies on diabetic patients.
RESEARCH METHODOLOGY
The search was done in databases of Google 
Scholar, Medline and Science Direct, using the key terms 
diabetes, plants, herbs, glucose and Patients. Only those 
medicinal plants with hypoglycemic actions shown by 
at least three clinical studies were incorporated in the 
manuscript. Antidiabetic effects of some plants (e.g. 
Opuntia streptacantha, Ipomoea batatas, Urtica dioica) 
have been reported by replicated studies of only one group 
of researchers. Results of these clinical studies have not 
been included in this paper.
ANTIDIABETIC HERBS
Aegle marmelos
Aegle marmelos, also known as bael, has been 
reported to have a number of medicinal attributes including 
antidiabetic effects. In a study by Ismail (2009a), twenty 
T2D patients with postprandial blood glucose (PPBG) of 
201 ± 6 mg/dL were given decoction of 5 g A. marmelos 
leaf powder once a day. After 16 weeks, their PPBG 
significantly decreased to 159 ± 5 mg/dL. In another study, 
it was also shown that this decoction (5 g/day for 1 month) 
potentiated hypoglycemic effect of standard oral drugs in 
T2D patients (Ismail, 2009b). The same finding was also 
reported by Sankhla et al. (2009). In their double blind 
placebo trial, T2D patients were given sulfonylurea drug 
plus A. marmelos leaves (2 g/twice a day) or sulfonylurea 
plus placebo. After 8 weeks, the combined therapy had 
more effects on the level of fasting blood glucose (FBG), 
PPBG and urinary glucose (Table I).
Allium cepa
Preliminary, Mathew and Augusti (1975) reported 
that oral consumption of Allium cepa (onion) can improve 
glycemic control in diabetes. Acute hypoglycemic effect 
of A. cepa was also observed in a self-controlled study 
on twenty patients with T2D. It was also able to attenuate 
(37%) rise in plasma glucose 2 h after glucose ingestion 
(Myint et al., 2009). More recently, it was shown that 
intake of 100 g A. cepa can decrease FBG level and 
improve glucose tolerance test (GTT) in both T1D and 
T2D patients (Eldin et al., 2010).
Gymnema sylvestre
Accumulating pieces of evidence demonstrates that 
leaves of Gymnema sylvestre (Gurmar, Meshashringi, 
Merasingi, Kavali, Dhuleti) can improve glycemic control 
in diabetes. Shanmugasundaram et al. (1990) evaluated 
effectiveness of G. sylvestre leaf extract in controlling 
hyperglycaemia in 27 T1D patients under insulin therapy. 
The extract (400 mg/day for 18 months) significantly 
decreased FBG, HbA1c and serum lipids of the patients 
when compared with a similar group who received only 
insulin. Also, administration of this extract (400 mg/day 
for 18-20 months) as a supplement to conventional oral 
hypoglycemic drugs reduced FBG and HbA1c of T2D 
patients and drug dosage could be decreased (Baskaran et 
al., 1990). In a study by Joffe and Freed (2001), diabetic 
patients were given a product containing G. sylvestre leaf 
extract (400 mg) twice a day. After 3 months, FBG and 
PPBG levels decreased by 11 and 13%, respectively. A 
0.6-0.8% decrease was also observed in HbA1c. In another 
trial, treatment of T2D patients with a G. sylvestre-based 
product (1 g/day for 2 months) led to significant decreases 
in FBG and PPBG levels which were accompanied by 
increases in circulating insulin and C-peptide. Moreover, 
it stimulated insulin secretion from isolated human islets of 
Langerhans (Al-Romaiyan et al., 2010). A mild decrease 
in FBG (1%) and PPBG (1%) levels was also seen in T2D 
patients (20 cases) treated for 4 weeks with 6 g/day of G. 
sylvestre leaf powder (Paliwal et al., 2009).
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TABLE I - Best herbs for managing diabetes
Herbs Cases Study Design Effects References
Aegle marmelos T2D
T2D
T2D
Controlled trial 
Controlled trial 
RDBP trial
↓PPBG
↑Oral hypoglycemic drugs actions
↑Oral hypoglycemic drugs actions
Ismail, 2009a
Ismail, 2009b
Sankhla et al., 2009
Allium cepa T2D
T2D
T1D&T2D
Pre- & Post-treatment
Pre- & Post-treatment
Controlled trial
↓FBG
↓blood glucose 2 h after sugar ingestion
↓FBG, ↑Glucose tolerance 
Mathew et al., 1975
Myint et al., 2009
Eldin, et al., 2010
Gymnema 
sylvestre
T1D
T2D
T2D
T2D
T2D
Controlled trial 
Controlled trial
Pre- & Post-treatment
Pre- & Post-treatment
Pre- & Post-treatment
↑Insulin actions
↑Oral hypoglycemic drugs actions
↓FBG, ↓PPBG, ↓HbA1c
↓FBG, ↓PPBG
↓FBG, ↓PPBG
Shanmugasundaram et al., 1990
Baskaran et al., 1990
Joffe et al., 2001
Al-Romaiyan et al., 2010
Paliwal et al., 2009
Momordica 
charantia
T1D&T2D
T2D
T2D
T2D
T2D
T2D
T2D
T2D
T1D&T2D
T2D
Pre- & Post-treatment
Pre- & Post-treatment
Pre- & Post-treatment
Pre- & Post-treatment
Pre- & Post-treatment
Pre- & Post-treatment
Controlled trial 
Controlled trial 
Controlled trial
RDBP trial
↓PPBG
↓FBG, ↓PPBG
↑Glucose tolerance 
↓FBG, ↓HbA1c
↓FBG, ↓HbA1c
↓FBG
↓FBG, ↓Lipids, ↓Retinopathy, ↓stroke
↓Fructosamine
↓FBG
Without significant effects
Grover et al., 1990
Ahmad et al., 1999
Welhinda et al., 1986
Sirvastava et al., 1993
Leatherdale et al., 1981
Waheed et al., 2008
Rahman et al., 2009
Fuangchan et al., 2011
Baldwa et al., 1977
Dans et al., 2007
Nigella sativa MS
T2D
T2D
T2D
Controlled trial 
Pre- & Post-treatment
Pre- & Post-treatment
Controlled trial
↓FBG, ↓Lipids
↓FBG, ↑Insulin
↑Oral hypoglycemic drugs actions
↓FBG, ↓Lipids, ↓Blood pressure
Najmi et al., 2008
Bilal et al., 2009
Bamosa et al., 2010
Qidwai et al., 2009
Ocimum sanctum T2D
T2D
T2D
Pre- & Post-treatment
Pre- & Post-treatment
RSBP trial
↓Polydypsia, ↓Polyphagia
↑hypoglycemic drugs actions, ↓Lipids
↓FBG, ↓PPBG, ↓Lipids, ↓Glucosuria
Kochhar et al., 2009
Rai et al., 1997
Agrawal et al., 1996
Panax 
quinquefolius
T2D
T2D
T2D
RSBP trial 
RSBP trial 
RDBP trial
↓PPBG
↓Area under curve of BG
↓FBG, ↓HbA1c, ↓Body weight
Vuksan et al., 2000a
Vuksan et al., 2000b
Sotaniemi et al., 1995
Salacia reticulate T2D
T2D 
T2D
RDBP cross over trial
RDBP trial
Controlled trial
↓FBG, ↓HbA1c
↓HbA1c
↓FBG, ↓HbA1c, ↓Lipids
Kajimoto et al., 2000
Jayawardena et al., 2005
Radha et al., 2009
Silybum 
marianum
T2D
T2D
T2D
CDP
CDP
CDP
RDBP trial 
RDBP trial
RDBP trial
Controlled trial 
Controlled trial 
Controlled trial
↓FBG,↓HbA1c,↓Lipids,↓Liver enzymes
↓FBG,↓HbA1c,↓Lipids,↓Liver enzymes
↑Oral hypoglycemic drugs actions
↓Random BG, ↓Liver enzymes
↓FBG, ↓HbA1c, ↓Glucosuria 
↓hyperinsulinemia, ↓Daily insulin need
Fallah Hoseini et al., 2006
Ramezani et al., 2008
Hussain, 2007
Jose et al., 2011
Velussi et al., 1997
Velussi et al., 1993
Trigonella 
foenum
T1D
T2D
T2D
T2D
T2D
T2D
T2D
T2D
Cross over trial 
Pre- & Post-treatment
Cross over trial
Pre- & Post-treatment
RDBP trial
Controlled trial 
Controlled trial 
RDBP trial
↓FBG, ↓Lipids, ↓Glucosuria
↓FBG, ↓Lipids
↓FBG, ↓Lipids, ↑Glucose tolerance 
↓PPBG
↑Oral hypoglycemic drugs actions
↑Glucose tolerance, ↓Lipids, ↓Glucosuria
↓FBG, ↓TG, ↓Lipids
↓Area under curve of BG, ↓Lipids, No significant 
effects on FBG or glucose tolerance 
Sharma et al., 1990b
Kassaian et al., 2009
Sharma et al., 1990a
Ismail, et al., 2009a
Fu-rong et al., 2008
Sharma, 1986
Mitra et al., 2006
Gupta et al., 2001
CDP: Cirrhotic diabetic patients; FBG: fasting blood glucose; MS: Metabolic syndrome; PPBG: postprandial blood glucose; 
RDBP: Randomized double-blind placebo; RSBP: Randomized Single-blind placebo; T1D: type-1 diabetes; T2D: type-2 diabetes; 
↓: Decrease; ↑: Increase
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Momordica charantia
Momordica charantia (Karela, Ampalaya, bitter 
melon, bitter gound) has acquired a reputation for 
management of diabetes. It has passed several animal 
studies and its clinical trials have been started since many 
years ago. Administration of M. charantia seeds to six 
T1D and fourteen T2D patients significantly decreased 
PPBG level in both patient groups (Grover Gupta, 1990). 
Also, drinking an aqueous suspension of the vegetable 
pulp resulted in remarkable reduction of FBG and PPBG 
levels in 86 out of 100 cases with moderate T2D (Ahmad 
et al., 1999). Similarly, fruit juice of M. charantia was 
found to significantly improve glucose tolerance in 73% 
of eighteen maturity onset diabetic patients (Welhinda 
et al., 1986). In a case series study, diabetic patients 
were given aqueous extract (7 cases) or dried powder (5 
cases) of M. charantia fruit, as a single dose or thrice a 
day, respectively. After 3 weeks, the extract and powder 
caused 54% and 25% reduction in mean blood glucose, 
respectively (Sirvastava et al., 1993). Also, HbA1c 
was reduced from 8.37 to 6.1% by the extract. In line 
with these findings, Leatherdale et al. (1981) found a 
decreased HbA1c in 9 patients with T2D who consumed 
fried M. charantia fruits (0.23 kg/day for 8-11 weeks) and 
also an improvement of glucose tolerance in the patients 
who had taken 50 ml of M. charantia juice. Consumption 
of dried powder of M. charantia fruit showed reduction 
in FBG of 10 T2D patients with no history of previous 
medication and 10 T2D patients with history of taking oral 
hypoglycemic agents. The same effect was also obtained 
with aqueous and alcoholic extracts of M. charantia fruit 
(Waheed et al., 2008). Recently, Rahman et al. (2009) 
compared effects of M. charantia and rosiglitazone, 
a thiazolidinedione derivative, between 25 T2D 
patients treated with M. charantia juice (55 mL/day 
for 5 months). The study showed that M. charantia was 
more effective in the management of diabetes (FBG, 
total cholesterol and serum sialic acid) and its related 
complications (retinopathy and myocardial infarction) 
than rosiglitazone. On the other hand, Fuangchan et al. 
(2011) reported that hypoglycemic effect of M. charantia 
was less than metformin. Besides, in their multicenter 
randomized double-blind study, fructosamine level 
significantly decreased in T2D patients who received 
M. charantia for 4 weeks. Unlike the above mentioned 
studies, Dans et al. (2007) reported no significant 
decrease in FBG and total cholesterol level of T2D 
patients treated with a M. charantia product (2 capsules/
three times daily) given for 3 months. They only observed 
a 0.24% decline in HbA1c following the intervention. 
In an attempt to test active compound underlying 
antidiabetic effect of M. charantia, a controlled clinical 
trial was performed on 9 diabetic patients using an 
insulin-like agent purified from this plant. Subcutaneous 
injection of the agent led to a remarkable fall in the blood 
glucose level after 30-60 min (Baldwa et al., 1977). Also, 
a hypoglycemic peptide (polypeptide-p) was isolated 
from fruits, seeds and tissues of M. charantia, which 
showed hypoglycemic effect when being subcutaneously 
administered to diabetic patients (Khanna et al., 1981).
Nigella sativa
Seeds of Nigella sativa (black seed) have been 
used for centuries as a natural remedy for various 
ailments. Hypoglycemic, antioxidant, hypotensive, 
hypolipidemic and antimicrobial effects of N. sativa have 
been experimentally reported (Mehta et al., 2012; Shafiee-
Nick et al., 2012). With clinical studies, its therapeutic 
effect in metabolic syndrome and diabetes has been 
shown in recent years. Administration of N. sativa oil 
(2.5 mL twice a day for 6 weeks) to patients with metabolic 
syndrome has significantly decreased FBG and LDL and 
increased high density lipoprotein (HDL) levels (Najmi et 
al., 2008). A significant decrease in FBG and increase in 
insulin and SGOT of 41 T2D patients has been observed 
after a 40 day treatment with N. sativa oil. Levels of blood 
urea, SGPT, total leukocyte and platelet have remained 
unchanged after treatment with oil (Bilal et al., 2009). In 
a study, N. sativa seeds (1, 2 or 3 g/day) were added to 
antidiabetic drugs of 94 T2D patients. After three months, 
a significant reduction occurred in FBG, PPBG and HbA1c 
levels (Bamosa et al., 2010). Favorable impact of N. sativa 
on blood glucose, serum lipids and blood pressure was also 
reported by Qidwai et al. (2009).
Ocimum sanctum
A significant decrease in diabetic symptoms 
(polydypsia, polyphagia and tiredness) has been seen in 
30 T2D patients consuming (2 g/day/for 3 months) leaf 
powder of Ocimum sanctum (Kochhar et al., 2009). One 
month dietary supplement with O. sanctum powder has 
also shown decreased FBG (21%) and glycated protein 
(11%), total cholesterol (11%), low density lipoprotein 
(LDL) (14%), very low density lipoprotein (VLDL) (16%) 
and triglyceride (TG) (16%) in 27 patients with T2D (Rai 
et al., 1997). Hypoglycemic and hypolipidemic effects 
were confirmed by Agrawal et al. (1996) in a randomized 
placebo-controlled, single blind trial performed on T2D 
patients.
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Panax quinquefolius
The most commonly used ginsengs are Panax 
ginseng (Korean or Chinese ginseng), Panax quinquefolius 
(American ginseng) and Panax japonicus (Japanese 
ginseng). American ginseng has been reported to attenuate 
PPBG level in 9 T2D patients. The area under curve 
of blood glucose is reduced by about 20% in patients 
receiving 3 g of ginseng (Vuksan et al., 2000a; Vuksan et 
al., 2000b). In a double blind placebo-controlled study, 
administration of ginseng (unknown species, 100 or 200 
mg/day for 8 weeks) to 36 T2D patients significantly 
decreased FBG, HbA1c and body weight (Sotaniemi et 
al., 1995). In contrast with P. quinquefolius, more recently, 
Reeds et al. (2011) showed that P. ginseng can not improve 
glucose tolerance in newly diagnosed T2D patients.
Salacia reticulate
It has been shown that a diet containing aqueous 
extract from the stem of Salacia reticulate (240 mg/day 
for 6 weeks) can decrease FBG and HbA1c levels in 
T2D patients (Kajimoto et al., 2000). Also, a significant 
reduction in HbA1c has been reported in the patients 
receiving a preparation of S. reticulate tea for 3 months 
(Jayawardena et al., 2005). Clinical usefulness of S. 
reticulate consumption (2 g/day for 3 months) in the 
management of diabetes has been also observed in 30 
patients (Radha, Amrithaveni, 2009).
Silybum marianum
The fame of Silybum marianum (milk thistle) seed 
in herbal medicine is owing to its therapeutic effects for 
liver-related disorders. However, beneficial effects of S. 
marianum and its flavonolignans (silymarin) on reducing 
glucose and lipids have been also shown in diabetic 
patients (Dixit et al., 2007). In a 2-month randomized 
double blind clinical study, silymarin (200 mg thrice a 
day) could decrease FBG, HbA1c, total cholesterol, LDL, 
TG, serum glutamic oxalacetic transaminase (SGOT) 
and serum glutamic pyruvic transaminase (SGPT) in 
T2D patients (30 cases) receiving conventional therapy 
(Fallah Hoseini et al., 2006). Reduction in glucose, 
lipids and hepatic enzymes is consistent with the results 
of another trial on 25 T2D patients receiving the same 
dose of silymarin for 4 months (Ramezani et al., 2008). 
Beneficial effects of silymarin (200 mg/day) on FBG, 
HbA1c and PPBG have been also seen in T2D patients 
maintained on glibenclamide (Hussain, 2007). It has been 
also reported that silymarin administration to diabetic 
patients with liver disease could reduce insulin resistance, 
endogenous insulin production and need for exogenous 
insulin administration (Jose et al., 2011; Velussi et al., 
1993; Velussi et al., 1997). Oral consumption of silymarin 
(600 mg/day for 4 months) significantly decreased FBG, 
HbA1c and glucosuria in insulin-treated diabetics with 
alcoholic cirrhosis (Velussi et al., 1997). Also, in another 
study, percentage reduction in FBG, SGOT and SGPT 
was about 8, 29 and 35%, respectively, after a 5 month 
treatment of the patients with silymarin (Jose et al., 2011).
Trigonella foenum-graecum
Hypoglycemic effect of Trigonella foenum-
graecum (fenugreek) seeds has been demonstrated in 
cell culture, animal models and human with more than 
30 studies (Ghorbani, Rakhshandeh, 2012). In human 
studies, usefulness of fenugreek seeds has been reported 
in management of both T1D and T2D. Sharma et al. 
(1990b) showed that defatted T. foenum-graecum seeds 
(100 g/day for 10 days) significantly reduced FBG, TG, 
total cholesterol, LDL, VLDL and glucoseuria in patients 
with T1D. In another study, patients with T2D were placed 
on 10 g/day T. foenum-graecum seeds soaked in hot water 
(11 subjects) or mixed with yoghurt (7 subjects). After 
8 weeks, FBG, TG and VLDL significantly decreased in 
cases which received the seeds in soaked form (Kassaian 
et al., 2009). Similarly, addition of T. foenum-graecum 
seeds (100 g) to diets of patients with T2D for 10 (15 
subjects) or 20 (15 subjects) days improved GTT and 
led to significant decrease in FBG, TG and LVDL levels 
(Sharma, Raghuran, 1990a). Ismail (2009a) extended 
period of study to 16 weeks, administrated 20 g/day of 
T. foenum-graecum seeds to 20 non-insulin dependent 
diabetic patients and reported a significant decrease 
in PPBG level. In a double blind placebo trial, T2D 
patients (46 cases) were given sulfonylureas drug plus 
T. foenum-graecum seeds (in the form of pill; 6 pills/3 
times per day) or sulfonylureas drug plus placebo (23 
cases). After 12 weeks, the combined therapy had more 
effect on level of FBG, HbA1c and PPBG (Fu-rong 
et al., 2008). With a similar trial design, Gupta et al. 
(2001) administrated 1 g/day hydroalcoholic extract of 
the seeds to 12 newly diagnosed patients with T2D for 
two months and found that the extract failed to change 
FBG and GTT; but, it could decrease serum TG and the 
area under curve of blood glucose. Also, an increase in 
HDL level and percent of insulin sensitivity (according 
to homeostatic model assessment) was observed in 
the treated subjects. According to the study of 5 non-
insulin dependent diabetic patients by Sharma (1986), 
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administration of defatted T. foenum-graecum seeds 
(25 g) for 3 weeks produced a significant improvement 
in GTT and insulin response and a significant decrease 
in serum cholesterol and 24 h urinary glucose output. In 
this study, a single dose of whole seeds, defatted seeds, 
gum isolate and cooked seeds (but not degummed seeds) 
of T. foenum-graecum was also able to prevent the rise of 
plasma glucose after meal or glucose ingestion in non-
diabetic subjects. Unlike the seeds, effect of T. foenum-
graecum leaves on reducing blood glucose level was 
not consistent. While Sharma (1986) observed negative 
results with cooked leaves, Abdel-Barry et al. (2000) 
reported that 40 mg/kg of aqueous extract of T. foenum-
graecum leaves can diminish blood glucose level of 
healthy subjects 4 h after ingestion, which may be due 
to methodological issues such as difference in methods 
of extract preparation.
CONCLUSION
Plants have always been an important source 
for finding new remedies for human diseases. Among 
hundreds of plants that have been studied for diabetes, 
only a small fraction has been tested in animal studies 
and is under clinical trials. The plants described in this 
paper, particularly Gymnema sylvestre, Momordica 
charantia and Trigonella foenum-graecum, had some 
clinical evidence for their antidiabetic effects. Therefore, 
it seems that physicians can rely on these herbs, at least 
as complementary therapeutics, along with current 
hypoglycemic drugs to improve management of diabetic 
patients.
Although a list of other plants could be also included 
in this paper, it is better to wait until more clinical pieces of 
evidence are available to support their hypoglycemic effect. 
For example, Allium sativum, Aloe vera, Azadirachta 
indica, Citrullus colocynthis, Eugenia jambolana, green 
tea, Morus indica, Pterocarpus marsupium, Phyllanthus 
amarus and Salacia oblonga, each of which has two 
supporting studies, could be on the list. On the other 
hand, regarding some herbs (e.g. Cinnamomum cassia), 
although a significant hypoglycemic effect has been 
found in some studies (Crawford, 2009; Khan et al., 2010; 
Mang et al., 2006), other reports have disapproved the 
findings (Blevins et al., 2007; Suppapitiporn, Kanpaksi, 
2006). Furthermore, in a number of studies, there are still 
some methodological flaws (e.g. small sample size, short 
duration of trial and lack of control or placebo groups). 
Therefore, based on the currently available evidence, it 
is too early for making conclusions on benefits of such 
plants in diabetes.
Taken together, it seems that Gymnema sylvestre, 
Momordica charantia, Silybum marianum and Trigonella 
foenum-graecum have acquired enough reputation for their 
hypoglycemic action and physicians can advise them for 
patients to improve management of diabetes.
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